Thursday, November 12, 2015 7:10:24 AM
The scope of the current project between Ulm and Theralase is to investigate the localization (where do they locate in the cell) and the MOA (how they work on the cell) of Theralase's lead PDC, TLD-1433, currently under investigation for the destruction of Non-Muscle Invasive Bladder Cancer ("NMIBC").
The head of the core facility "Confocal and Multiphoton Microscopy", located in the Medical Faculty of Ulm, is Dr. Angelika Rueck, who will be conducting the research.
The heart of the facility consists of two laser-scanning microscopes capable of live cell imaging through detailed Fluorescence Lifetime Imaging Microscopy ("FLIM") and Phosphorescence Lifetime Imaging Microscopy ("PLIM").
More detail on the facility, led by Dr. Rueck, is available at:
http://fakultaet.medizin.uni-ulm.de/fileadmin/Forschung/research-infrastructure.pdf
Dr. Rueck was instrumental in assisting Theralase with microscopy analysis of its recent research entitled, "A novel class of ruthenium-based photosensitizers effectively kills in vitro cancer cells and in vivo tumors."
https://globalmedicaldiscovery.com/key-drug-discovery-articles/a-novel-class-of-ruthenium-based-photosensitizers-effectively-kills-in-vitro-cancer-cells-and-in-vivo-tumors/
Under the current research agreement, Dr. Rueck will determine the localization and MOA of TLD-1433 through the following phases:
Phase 1 - Intracellular localization of TLD-1433 and cytotoxicity (cell kill) will be investigated in two (2) different urothelial carcinoma tumour cell lines (HT1376 and T24) and one (1) normal human urothelial cell line as a function of time.
Phase 2 - FLIM and PLIM will be completed to more fully understand how TLD-1433 affects cancer cell metabolism and to identify the MOA of mediated cell death by this PDC.
Phase 3 - Cell metabolism in the three cell lines, in the presence and not of TLD-1433 will be analyzed.
Roger Dumoulin-White, President and CEO, Theralase stated that, "It is indeed a great pleasure to work with a scientist as renowned in her field as Dr. Rueck. Her research will be instrumental in helping Theralase to unlock the exact mechanisms of our PDCs in cancer cells and provide MOAs as to why the Theralase PDCs are so effective in the destruction of cancer cells. I look forward to reporting out on Dr. Rueck's research in due course."
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM